AACR 2026

At the AACR Annual Meeting 2026, discussions will centre on how to generate preclinical oncology data that supports successful funding milestones and enables confident development decisions.

We will be available to discuss how robust preclinical pharmacology can strengthen candidate validation by enabling detailed interrogation of mechanism, biodistribution, and therapeutic impact in clinically relevant settings. From model selection through to translational study design, the focus is on generating data that reduces uncertainty, supports informed decision-making, and clarifies next steps toward the clinic.

We are joined at the meeting by our Head of Radiotherapy and Pharmaco-Imaging, reflecting the growing role of targeted radiopharmaceuticals as a powerful pathway for validated cancer candidates.

Book a meeting and visit our booth (#3442) to explore how a scientifically rigorous approach to preclinical evaluation can help advance oncology programmes with clarity and confidence.

Not affiliated with or endorsed by AACR.

Book a meeting with our team at AACR